Coast Quality Pharmacy, LLC, Tampa, FL

Is Coast Quality Pharmacy, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Coast Quality Pharmacy, LLC hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 4 licenses for this name and city, as of Nov 15, 2026: PH28368 for COAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH), TAMPA, status Closed, PH28369 for COAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH), TAMPA, status Closed, PH28370 for COAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH), TAMPA, status Closed and PH28371 for COAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH), TAMPA, status Closed. The Colorado State Board of Pharmacy also lists nonresident license OSP 5145 for Coast Quality Pharmacy, Tampa, FL, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018807 for COAST QUALITY PHARMACY LLC, TAMPA, FL, status CHANGE OF OWNERSHIP and license 054019467 for COAST QUALITY PHARMACY LLC, TAMPA, FL, status CLOSED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002787 for COAST QUALITY PHARMACY LLC (dba ANAZAOHEALTH), TAMPA, FL, status CLOSED and license PCN.0003173 for COAST QUALITY PHARMACY LLC (dba ANAZAOHEALTH), TAMPA, FL, status CLOSED (WITHDRAWN), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001514 for Coast Quality Pharmacy, LLC (dba Anazaohealth), TAMPA, FL, status Closed, as of Nov 10, 2026.

Has Coast Quality Pharmacy, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Jun 29, 2022) for Coast Quality Pharmacy, LLC. State board actions: no Florida Board of Pharmacy action on licenses PH28368, PH28369, PH28370 and PH28371 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Coast Quality Pharmacy, LLC
Location
Tampa, FL
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 29, 2022
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 4 published Form 483s
Form 483 text on this page
3 Form 483s, 30 observations
State board records
License found: PH28368, Closed; PH28369, Closed; PH28370, Closed; PH28371, Closed

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Coast Quality Pharmacy, LLC, a 503A facility, with 2 dated actions.

Document
Jun 29, 2022FMD-145 letterFMD-145 Letter Issued 06/29/2022Not linked by FDA
May 9, 2019Form 483483 Issued 05/09/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Coast Quality Pharmacy, LLC, Tampa, FL (FEI number 3004483463), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 9, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30044834631089129
May 7, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30044834631051024

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 30 numbered observations in all, across 3 inspections ending Feb 22, 2013 to May 9, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Apr 25, 2019 to May 9, 2019: 5 observations

Firm on the cover
Coast Quality Pharmacy, LLC dba Anazao Health, 5710 Hoover Blvd, Tampa, FL 33634 -5339
FEI number
3004483463
Establishment type on the cover
Producer of Sterile and non-sterile drugs
FDA district office on the cover
555 Winderley Place, Suit e 200 Mait land, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.

Specifically,

A. For OOS-2019-0003: a sterility failure (Bacillus subtilus) was received by your firm on 01/31/19 for ACD solution, Lot ACD190129RA, produced on 01/29/19 in ISO 5 Hood <Redacted B4> located in non­radiophamaceutical room, <Redacted B4> Per OOS-2019-0003, the root cause of the sterility failure was identified as "the environment in room[~ The <Redacted B4> table was contaminated with B. subtilus group" In addition, Bacillus subtilus was cultureoon 01/16719 from surface sampling taken of the <Redacted B4> table used to prep vials prior to placement into the ISO 5 Hood and to <Redacted B4> vials after the placement of the cap after lyophilization. ACD solution, Lot ACD190129RA was d1scru·ded however your firm failed to evaluate the potential impact on additional sterile drug products produced in room <Redacted B4> from 01/16/19 to 01/29/19. ...

Read the full 483 (PDF on fda.gov)

Observation 2

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, your firm failed to use pharmaceutical grade components for which there is a USP/NF monograph:

(b) <Redacted B4> used to prepare radiophaimaceuticals such as In-111-DTP A for cistemography

I

Diethylenetriaminepentaacetic acid (DTPA) used to prepare radiopharmaceuticals ls such as In-111-DTPA and non-radiophaimaceuticals such as DTPA Cold Kits

Sodium Iodide I-123 used to prepare radiopharmaceuticals such as I-123 MIBG

Sodium Iodide I-131 used to prepare radiopharmaceuticals is such as I-131 capsules

<Redacted B4> used to prepare radiopharmaceuticals such as 51 Chromium Chromate 0.l00mCi/mL

I

0.l00mCi/mL

This is a repeat observation from the inspection performed 04/09/18-05/07/18.

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

A. High risk media fills are not representative of the maximum batch size for aseptic operations for non-radiopharmaceutical drugs produced in vials and IV bags. For example:

Operators performed high risk media fills consisting of your firm's maximum batch size of <Redacted B4> vials only <Redacted B4>.

• Ooerators performed high risk media fills consisting of your firm's maximum batch size <Redacted B4> bags only <Redacted B4>

B. Your firm lacks validations for your <Redacted B4> machines used in the production of sterile Sincalide (CCK), Sodium I-123 MIBG, Bicisate (ECD), Exametazime (HMPAO), Mebrofenin, Mertiatide, Pentetate (DTPA), Pyrophosphate (PYP), Red Blood Cell (RBC), Succimer (DMSA), Sestamibi, and Tetrofosmin. (This is a repeat observation from the inspection performed 04/09/18-05/07/I8.)

C. ...

Read the full 483 (PDF on fda.gov)

Observation 4

The written stability program for drug products does not include reliable, meaningful and specific test methods.

Specifically, your stability test results for radiopharmaceutical and non-radiopharmaceutical sterile drugs prepared by your firm does not include testing and results at meaningful time intervals for your established beyond use dates for the following:

Chemical impurities

Microorganisms

Yeasts and molds

Endotoxins

This is a repeat observation from the inspection performed 04/09/18 - 05/07/18.

Observation 5

Disinfecting agents and used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically, your firm failed to use sterile cleaning agents in the routine cleaning of ISO 5 LAFW and BSC hoods and the nuclear and pain medicine ISO 7 clean rooms. Examples of non-sterile cleaning agents include, but are not limited to the following:

• <Redacte d B4> <Redacted B4> does not appear to be high enough to be sporicidal <Redacted B4> of <Redacted B4> with <Redacted B4> of non-stenle water).

J •

Inspection Apr 9, 2018 to May 7, 2018: 13 observations

Firm on the cover
Coast Quality Pharmacy LLC, 5710 Hoover Blvd, Tampa, FL 33634 -5339
FEI number
3004483463
Establishment type on the cover
Preparer of sterile and non-sterile drug products
FDA district office on the cover
Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, the components In <Redacted B4> and diethylenetriaminepentaacetic acid (DTPA) used to prepare radiophaim aceuticals such as In <Redacted B4> DTPA for cistemography are a non-pharmaceutical grade and have not been tested for microorganisms or endotoxins by the manufacturer. You do not perform and have not performed the following testing on the <Redacted B4>

1.) Chemical impurities such as Cd which is the target material

2.) Radiochemical purity

3.) Radionuclide purity

4.) Microorganisms

5.) Yeasts and Mold

6.) Endotoxins

In addition on 4/12/2018, we also observed the following during the sterile disparations of <Redacted B4> lot In-DTPA180412RA for intrathecal use using <Redacted B4> ll DTPA lot <Redacted B4> made using DTP A lot <Redacted B4> in the Dispensing-clean room: <Redacted B4> was removed from the stock vial containing <Redacted B4> needle and syringe. The -Some of this was then returned back into the stock bottle using the same needle and syringe when it was detenrmined that the <Redacted B4>. This practice could increase the endotoxin load.

needle and syringe. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, we observed the following deficiencies:

A. Procedures have not been established for performing and evaluating smoke studies under dynamic conditions. In addition, your form lacks smoke studies demonstrating unidirectional laminar airflow during the most complex processes performed at your facility.

B. Ill

E

nvironmental total monitoring of the ISO 7 Dispensing-buffer room and the Ante room IS0 8 recovered in the past 3 months the following objectionable organisms and collective actions and preventive actions were not documented to demonstrate appropriate measures to remove these objectionable organisms: In Buffer Room ISO <Redacted B4>:

Ill Environmental total monitoring of the ISO 7 Dispensing-buffer room and the Ante room IS0 8 recovered in the past 3 months the following objectionable organisms and collective actions and preventive actions were not documented to demonstrate appropriate measures to remove these objectionable organisms: In Buffer Room ISO <Redacted B4>:

1.) Coagulase-negative Staphylococcus ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A. Surface and air monitoring of the IS0-5 classified laminar airflow workstations (LAFW) is not conducted at least daily, despite production of sterile drug products.

B. Personnel monitoring, including fingertip sampling, of operators involved in sterile operations of intrathecal drug products in the IS0-5 LAFW is not conducted at least daily.

(This is a repeat from the previous inspection date 02119-22113)

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. The suitability, efficacy, and limitations of disinfecting agents and procedures have not been assessed to ensure potential contaminants are adequately removed from surfaces in the ISO classified areas. (This is a repeat from the previous inspection date 02119­22113)

B.<Redacted B4> laminar flow hoods located in clean room <Redacted B4> had observable cracks in the plastic which is located directly over the ISO 5 areas where your filling operations are performed for -without the use of <Redacted B4>

Observation 5

Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components, drug product containers and closures.

Specifically, your firm accepts components (excipients), containers (glass vials, bags, syringes), and closures (rubber stoppers) without sampling and examination to ensure they are adequate for their intended use. In addition, your firm lacked written procedures and specifications for the control and acceptance of all containers and closures. (This is a repeat from the previous inspection date 02119­22113)

Observation 6

Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product.

Specifically, batches of <Redacted B4> were documented as discarded in your drug preparation documentation and reference to the investigation and extending this investigation to other batches was not documented. Examples of this include:

1 .<Redacted B4> lot <Redacted B4> for radiochemical purity.

2 .<Redacted B4> lot <Redacted B4> and <Redacted B4> for liver uptake.

3 .<Redacted B4> lot <Redacted B4> and <Redacted B4> for particle size.

Observation 7

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically, dispensing room - which was qualified as an ISO 7 buffer room containing <Redacted B4> laminar flow hoods qualified as an ISO 5 where the sterile drug filling of vials for lyophilization containing for injection is performed did not have air return vents and exit air flow was achieved through the area around the stainless steel swing door.

Observation 8

The written stability program for drug products does not include reliable, meaningful and specific test methods.

Specifically, your stability test results for lyophilized sterile drugs prepared by your firm does not include testing and results at meaningful time intervals for your established beyond use dates for the following:

1.) Chemical impurities

2.) Microorganisms

3.) Yeasts and Mold

4.) Endotoxins

Observation 9

Equipment was and Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically, we observed the following poor aseptic techniques prior to sterile drug preparations in the ISO 5 work bench:

A. On 4/11/2018, we observed the following during the sterile drug preparations of Baclofen 4mg/mL Premix, lot , and Morphine 50mg/mL Premix, lot <Redacted B4> both for intrathecal use:

1. We observed operators placing non-sterile wipes into the ISO 5 LAFW prior to the addition of

sterile <Redacted B4>. (This is a repeat from the previous inspection date 02119-22113) 2. Operators placed items including a scale,

a heater, and a wrapped glass flask, into the ISO 5 LAFWs prior to sterilizing with sterile

B. On 4/12/2018, we observed the following <Redacted B4> sterile ­reparations of <Redacted B4> DTTPA lot In-DTPA180412RA for intrathecal use using <Redacted B4> of <Redacted B4> in the Dispensing -clean room:

1. The stopper on the <Redacted B4> individually wiped off using an <Redacted B4> pad with metal tongs that were hung on a h~ebiological safety cabinet (BSC. <Redacted B4> end rather than the handle. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Personnel moved rapidly in the vicinity of open sterile units and instruments which disrupted the airflow and increased the risk of bringing lesser quality air into the ISO 5 classified aseptic processing area.

Specifically, we observed operators performing rapid movements while preparing intrathecal baclofen and morphine sterile drug preparations within the ISO 5 LAFWs on 04/09/18 and 04/11/18.

Observation 11

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically, we observed the <Redacted B4> gowning techniques during the sterile durations of Baclofen 4mg/mL Premix, lot~and Morphine 50mg/mL Premix, lot ) <Redacted B4> both for intrathecal use:

1. Operators exhibited poor gowning techniques, which per the Quality Assurance Manager, were the procedures routinely used by the firm. Examples include, but are not limited to: hanging sterile gown on non-sterile rack prior to donning gown and touching sleeves with bare hands prior to donning sterile gloves. 2. Per your procedure P-404, Hand Hygiene and Garbing Procedure, operators are to don a < Redacted B4> or equivalent garment. All operators observed on wore a sterile gown, with non-sterile bouffant and shoe covers.

3. The operator who produced Morphine 50mg/mL Premix, Lot went behind the ISO 5 laminar airflow workstation (LAFW) to plug in the scale and touched the back of the ISO 5 hoods and the ISO 7 wall. The operator donned new sterile gloves however she did not re-gown prior to continuing operations in the ISO 5 hood. 4. ...

Read the full 483 (PDF on fda.gov)

Observation 12

The ISO 5 classified aseptic processing ai·eas and segregated production areas surrounding the ISO 5 classified aseptic processing area contained dust-collecting overhangs without adequate and frequent cleaning.

Specifically,

A. We observed exposed <Redacted B4> filters on the top of a <Redacted B4> 5 LAFWs in Clean room which do not allow for complete sanitization of the ISO 5 LAFWs.

B.) Your bio safety cabinet liocated in your clean room lwhere you prepare In <Redacted B4> DTPA had visible peeling duck tape on the side of the cabinet that appeared to be covering two electric wire pass through holes that opened up directly to the ISO 5 work area where semi-aseptic diug preparations are performed.

Observation 13

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.

Specifically, on 02/23/18, an out-of-specification (OOS) that recovered Coagulase-negative Staphylococcus spp. for routine Gloved Fingertip Sampling (GFS right 3 colonies and GFS left 16 colonies) performed on 02/20/18 was observed by your firm. The investigation performed is deficient for the following reasons: the investigation does not document if additional videos were reviewed and the results of those video reviews; the investigation does not addi·ess the potential contamination risks of the batch produced immediately prior to the positive GFS; and the investigation does not extend to additional batches produced on 02/20/18 by the employee.

the batch produced immediately prior to the positive GFS; and the investigation does not extend to additional batches produced on 02/20/18 by the employee.

Inspection Feb 19, 2013 to Feb 22, 2013: 12 observations

Firm on the cover
Anazaohealth Corporation, 5710 Hoover Blvd, Tampa, FL 33634-5339
FEI number
3004483463
Establishment type on the cover
Producer of sterile products
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products pillporting to be sterile are not established, written, and followed.

Specifically,

The Pain Management media fills do not simulate production processes under nonnal operating conditions. Some deficiencies include but are not limited to:

a) SOP P-403 "Pain Management Premix process verification of sterile compounding fill" and SOP P-402.2 "Pain Management Media Fill and Process Verification" is deficient in that:

1. The operator mixes the non-sterile REDACTED (b)(4) media powder in an uncontrolled area instead of hte ISO 7 area where non-sterile powders are handled during routine production. 2. The filled beaker where this media is prepared is sanitized REDACTED (b)(4) times with REDACTED (b)(4) and REDACTED (b)(4) prior to entering it into the ISO 7 area and ISO 5 hoods thus exposing the open media to disinfectants. 3. Growth promotion tests are not conducted on the media used for media fills. 4. As per SOP P-403, no environmental monitoring, i.e. fingertip, air and surface, is conducted during media fills. 5. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include

validation of the sterilization process.

Specifically,

a) your firm failed to validate the REDACTED (b)(4) filters used to st erilize REDACTED (b)(4) products produced by your firm from non-sterile components. In addition, your firmhas not established pre-filtration bioburden limits in order to determine if it exceeds the maximum retention capability of the filter. your firm failed to validate the REDACTED (b)(4) filters used to sterilize REDACTED (b)(4) products produced by your firm from non-sterile components. In addition, your firmhas not established pre-filtration bioburden limits in order to determine if it exceeds the maximum retention capability of the filter.

b)REDACTED ( b) (4) sterilization process parameters in use for liquid nuclear preparations differ from the validated processing parameters, in some cases (extent unknown, pending receipt of additional records on 2-22-13). Sterilization time and REDACTED (b) (4) were both decreased, while (in some cases) container sizes and volumes were increased and “pig” shields were added. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Samples taken of drug products for determination of conformance to written specifications are not representative.

Specifically, sterility samples are collected from a bulk stock solution in a beaker REDACTED ( b) (4), prior to transfer in to REDACTED (b) (4) into syringes. No finished drug product testing in its final contai ner closure system is performed.

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring envirorunental conditions.

Specifically,

a) Surface and air monitoring of the IS0-5 classified laminar airflow workstations (LAFW) is not conducted at least daily, despite production of sterile drug products.

b) Personnel monitoring, including fmgertip sampling, of operators involved in sterile operations ofintrathecal drug products in the IS0-5 LAFW is not conducted at least daily.

c) The fum failed to investigate excursions in their environmental monitoring program whereby viable air samples within the IS0-7 classified compounding pharmacy were found to exceed Action Levels.

Observation 5

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically,

a)Operators performing aseptic operations in ISO 5 hoods re-use sterile cloth gowns throughout a production day. A s sampling of sleeves is not performed, your firm has no assurance that the sterility of hte sleeves is maintained. Operators performing aseptic operations in ISO 5 hoods re-use sterile cloth gowns throughout a production day. As sampling of sleeves is not performed, your firm has no assurance that the sterility of hte sleeves is maintained.

b)Large open packages containing multiple pairs of REDACTED (b) (4) gloves were observed in the nuclear ISO 8 gowning area. These gloves are used in the nuclear clean rooms to perform aseptic operations. The bag is dated when opened but there are no controls to prevent their use in aseptic operations once sterility is compromised. Large open packages containing multiple pairs of REDACTED (b) (4) gloves were observed in the nuclear ISO 8 gowning are a. These gloves are used in the nuclear clean rooms to perform aseptic operations. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

a) The suitability, efficacy, and limitations of disinfecting agents and procedures has not been assessed to ensure potential contaminants are adequately removed from surfaces in the ISO classified areas.

b) Routine cleaning procedures ofthe IS0-5 classified LAFW do not include the use ofa qualified sporicidal cleaning agent at established frequencies.

c) Non-sterile wipes are used to clean the ISO 5 LAFWs.

Observation 7

Time limits are not established when appropriate for the completion ofeach production phase to assure the quality ofthe drug product.

Specifically, your finn lacked adequate data to support the 5-month expiration date (hold time) ofthe bulk sterile pre-mix bags for the preparation ofintrathecal drugs.

Observation 8

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards ofidentity, strength, quality and purity at the time ofuse.

Specifically, your fum assigns a 90-day expiration date to all intrathecal drug products without adequate stability data tested with stability-indicating methods.

Observation 9

Drug product containers and closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.

Specifically,

a)There is no data to demonstrate that the non-sterile 50cc amber glass vials and rubber stoppers repackaged by your firm in uncontrolled areas for sterilization by REDACTED (b)(4) are sterile and free of pyrogens and particulates prior to being filled with Phosphatidylcholine solution for injection. There is no data to demonstrate that the non-ste rile 50cc amber glass vials and rubber stoppers repackaged by your firm in uncontrolled areas for sterilization by REDACTED (b)(4) are sterile and free of pyrogens and particulates prior to being filled with Phosphatidylcholine solution for injection.

b)Rubber stoppers are routinely sprayed directly with REDACTED (b) (4) in ISO 5 hoods prior to use in sterile operations to cap product vials of injectable drug products. There is no data to demonstrate that REDACTED (b) (4) residue on the product contact surfaces of the stoppers would not alter the quality, purity and strength of the sterile drug product. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval, and rejection ofcomponents, drug product containers, and closures.

Specifically, your firm accepts components (excipients), containers (glass vials, bags, syringes), and closures (rubber stoppers) without sampling and examination to ensure they are adequate for their intended use. In addition, your firm lacked written procedures and specifications for the control and acceptance ofall containers and closures.

Observation 11

Test procedures relative to appropriate laboratory testing for pyrogens are not written and followed.

Specifically,

a)Each lot of REDACTED ( b) (4) cartridges for endotoxin testing is not qualified upon receipt to demonstrate it performs as intended. Each lot of REDACTED (b) (4) cartridges for endotoxin testing is not qualified upon receipt to demonstrate it performs as intended.

b) Non-depyrogenated glass vials and rubber stoppers are used in the performance ofendotoxin testing ofall sterile injectable drug products.

Observation 12

Routine calibration and inspection of mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically,

a)REDACTED (b)(4) calibration/testing is not required by the firm's procedures, and was not performed by the service technician during REDACTED (b)(4) certifications. REDACTED (b)(4) ca libration/testing is not required by the firm's procedures, and was not performed by the service technician during REDACTED (b)(4) certifications.

b) REDACTED (b) (4) timers have not been checked/calibrated, as required by the firm’s procedure.

c) The calibration of thermometers used in Refrigerators# 5 & 6 in the nuclear processing areas expired on 3/24112. These refrigerators were observed as containing multiple batches ofsterile injectable products in glass vials awaiting test results or

prescriptions before dispensing.

d) The thennometers in refrigerators located in the pain management area were not identified and lacked calibration dates.

Linked 483s whose text is not shown

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH28368PharmacyCOAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH)TAMPAClosed
PH28369PharmacyCOAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH)TAMPAClosed
PH28370PharmacyCOAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH)TAMPAClosed
PH28371PharmacyCOAST QUALITY PHARMACY, LLC (dba ANAZAO HEALTH)TAMPAClosed

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5145OSPCoast Quality PharmacyTampa, FLExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054018807LICENSED PHARMACYCOAST QUALITY PHARMACY LLCTAMPA, FLCHANGE OF OWNERSHIP
054019467LICENSED PHARMACYCOAST QUALITY PHARMACY LLCTAMPA, FLCLOSED

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002787NONRESIDENT PHARMACYCOAST QUALITY PHARMACY LLC (dba ANAZAOHEALTH)TAMPA, FLCLOSED
PCN.0003173NONRESIDENT PHARMACYCOAST QUALITY PHARMACY LLC (dba ANAZAOHEALTH)TAMPA, FLCLOSED (WITHDRAWN)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001514Non Resident PharmacyCoast Quality Pharmacy, LLC (dba Anazaohealth)TAMPA, FLClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.